MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
6.81
-0.13
-1.87%
Opening 09:30 11/04 EST
OPEN
6.83
PREV CLOSE
6.94
HIGH
6.83
LOW
6.78
VOLUME
27.89K
TURNOVER
--
52 WEEK HIGH
11.40
52 WEEK LOW
3.260
MARKET CAP
575.01M
P/E (TTM)
-5.1882
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TERN last week (1028-1101)?
Weekly Report · 11h ago
Optimistic Outlook for Terns Pharmaceuticals: Potential of TERN-701 Amidst Market Opportunities
TipRanks · 3d ago
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 4d ago
Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
TipRanks · 4d ago
Terns Pharmaceuticals Price Target Announced at $17.00/Share by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Initiates Coverage On Terns Pharma with Outperform Rating, Announces Price Target of $17
Benzinga · 4d ago
Terns Pharmaceuticals initiated with an Outperform at Oppenheimer
TipRanks · 4d ago
Weekly Report: what happened at TERN last week (1021-1025)?
Weekly Report · 10/28 09:16
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.